Scott Hutton - Feb 23, 2021 Form 4 Insider Report for BIODESIX INC (BDSX)

Role
President & CEO, Director
Signature
/s/ Robin H. Cowie as Attorney-in-Fact for Scott Hutton
Stock symbol
BDSX
Transactions as of
Feb 23, 2021
Transactions value $
$0
Form type
4
Date filed
3/14/2022, 05:51 PM
Next filing
Nov 18, 2021

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BDSX Stock Options (Right to buy) Award $0 +8.42K $0.00 8.42K Feb 23, 2021 Common Stock 8.42K $0.77 Direct F1, F2
transaction BDSX Stock Options (Right to buy) Award $0 +8.42K +100% $0.00 16.8K Mar 10, 2022 Common Stock 8.42K $0.77 Direct F1, F3
transaction BDSX Stock Options (Right to buy) Award $0 +85.9K $0.00 85.9K Mar 10, 2022 Common Stock 85.9K $2.29 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On March 22, 2019, the Reporting Person was granted an option to purchase 25,269 shares (as-adjusted for the 0.1684664-for-1 reverse stock split effected on October 19, 2020), the vesting of which was subject to the Issuer's satisfaction of certain performance criteria for each of the 2019, 2020 and 2021 fiscal years. The performance criteria was not met for fiscal year 2019, resulting in the cancellation of 8,423 shares underlying the option.
F2 On February 23, 2021, the Compensation Committee of the Issuer's board of directors (the "Compensation Committee") confirmed the performance criteria were met for fiscal year 2020, resulting in the vesting of 8,423 shares underlying the option.
F3 On March 10, 2022, the Compensation Committee confirmed the performance criteria were met for fiscal year 2021, resulting in the vesting of 8,423 shares underlying the option.